Pharmetheus ads

Peter Milligan, retiring CEO of Pharmetheus, wins International Society of Pharmacometrics (ISoP) Leadership Award 2026 🌟 After seven successful years, former CEO Peter Milligan leaves Pharmetheus at one of the major milestones of his career. ISoP announced earlier this summer that he has won the Leadership Award in recognition of his many achievements at Pharmetheus and in the field of pharmacometrics. The Leadership award is presented at the American Conference of Pharmacometrics (#ACoP) later this fall, where Peter Milligan will be present to accept. “The ISoP Leadership Award was a wonderful surprise. Stepping down as CEO makes the timing feel like a perfect bookend”, he says. Watch the interview below or read the article at https://lnkd.in/dnNFSkRY Thank you for your years of leadership, Peter, and congratulations on your award!

While CAR-T cell therapy has revolutionized hematological cancer treatment, hurdles remain. Because CAR-T cells proliferate inside the patient, traditional dose-optimization strategies, where a higher dose leads to higher exposure, do not apply. Model-informed drug development can bridge this gap. Join us in this webinar, as Dr. Anna Mc Laughlin shares her insights into opportunities for cell therapy in oncology. Key topics: ➡️ Review the fundamentals of CAR-T cell kinetics and why conventional dose optimization falls short. ➡️ Biological and clinical factors that drive exposure and response. ➡️ Properties of a fit-for-purpose model-informed drug development framework for cell therapy. ➡️ Walk through a mechanism-based population PK case study in hematological malignancies. ➡️ Learn how this quantitative foundation can support future portfolio decisions, such as cross-indication bridging and cross-modality translation. ➡️ Bridging from oncology to other indications. 🗓️ 8 October ⏱ 10:00 AM EDT / 4:00 PM CEST / 7:30 PM IST

"Time to event modeling is the perfect balance between relevance of outcome and granularity of data." Master TTE and RTTE modeling in NONMEM at American Conference of Pharmacometrics (ACoP) 2026! 📊 Pharmetheus is hosting a 1.5-day hands-on workshop designed to take your pharmacometric modeling skills to the next level. What to expect: • Practical TTE & RTTE theory and real-world applications • Live, step-by-step NONMEM coding and diagnostics • Insights from guest speakers France Mentre, Lena Friberg, and Brendan Bender • Hands-on support from tutors Jurgen Langenhorst and Qing Xi Ooi Whether you're a student or an experienced pharmacometrician, this session will give you the practical code and confidence you need. 👉 Register today: https://lnkd.in/dKx5fGNP

ICH M15 provides a common framework for planning, evaluating, and communicating Model-Informed Drug Development evidence in support of regulatory decision-making. But what does that look like in practice? Join our free webinar to learn more about: ➡️ How the guideline can be applied across the MIDD evidence lifecycle, from defining the regulatory question and context of use, to considering model credibility and risk, and presenting the evidence clearly for regulatory review. ➡️ How the ICH M15 principles can support a regulatory decision, using a practical case study to illustrate. ➡️ How it can support earlier planning, better cross-functional alignment, and more consistent evidence generation and reporting, alongside practical approaches for maintaining submission readiness under tight timelines. The webinar is held by Dr. Emma Hansson, Senior Director, Regulatory Affairs, and Dr. Martin Bergstrand, Principal Director, MIDD Scientific Lead. Date: Thursday, October 1, 2026 Time: 9:30 AM EDT / 3:30 PM CEST Duration: 60 Minutes (45 min presentation + 15 min live Q&A)

Are you asking your QSP CRO the right questions? Not all models are created equal. When navigating QSP CRO partnerships, ensuring your integration is built on a foundation of clinical confidence is critical. But how do you evaluate a model’s clinical relevance without compromising intellectual property? We've put together a practical framework of key questions to guide your due diligence. Equip your team with the right questions—download the checklist today ⬇

Are you asking your QSP CRO the right questions? Not all models are created equal. When navigating QSP CRO partnerships, ensuring your integration is built on a foundation of clinical confidence is critical. But how do you evaluate a model’s clinical relevance without compromising intellectual property? We've put together a practical framework of key questions to guide your due diligence. Equip your team with the right questions—download our checklist today ⬇